NASHUA, N.H., Oct. 30 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that Robert Howard, Founder and Chairman of the Board, has informed the Company of his decision to retire, effective November 1, 2007, from his position as iCAD’s Chairman to devote more time to personal and philanthropic activities.
Robert Howard, Chairman since the Company was established in 1984, was Chief Executive Officer of the Company from February 1984 until December of 1993. Mr. Howard also founded and served from 1969 to 1980 as President and Chairman of the Board of Centronics Data Computer Corp., a manufacturer of a variety of computer printers, including the first impact dot matrix printer, which Mr. Howard invented. He resigned from Centronics’ Board of Directors in 1983. In mid-1982, Mr. Howard established R.H. Research, where he developed the ink jet technology upon which iCAD was initially based and he contributed this technology, without compensation to the Company. Mr. Howard was Chairman of the Board of Presstek, Inc., a public company which developed proprietary imaging and consumables technologies for the printing and graphic arts industries, from July 1988 to September 1998. Mr. Howard was Co-Founder and Chairman of the Board of Ionatron, Inc., his 27th Company, a public company involved in the development and marketing of laser directed energy weapon technology and products that include directed energy weapons for defense and security customers primarily in the U.S. Government, from its inception in 2002 until he resigned as its Chairman and a director in March 2006.
“Bob Howard’s ongoing innovation and entrepreneurship is an inspiration to us all,” said Ken Ferry, President and Chief Executive Officer. “He achieved his goals through perseverance, commitment and a passion for making a difference. Thanks to his foresight and dedication, iCAD has become an industry leader in developing and commercializing CAD solutions for the early detection of cancer. I know I speak for all of my colleagues in wishing him a long, happy and healthy retirement.”
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at ddeptula@icadmed.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at icad@lhai.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
CONTACT: Darlene Deptula-Hicks, EVP and CFO of iCAD, Inc., +1-603-882-5200
ext. 7944, ddeptula@icadmed.com; or Investor Relations, Anne Marie Fields
of Lippert Heilshorn & Associates, +1-212-838-3777, ext. 6604,
icad@lhai.com, or Public Relations, Wendy Ryan of Schwartz Communications,
+1-781-684-0770, icad@schwartz-pr.com, both for iCAD, Inc.
Web site: http://www.icadmed.com/
